Combined effect of unsaturated fatty acids and saturated fatty acids on the metabolic syndrome: Tehran lipid and glucose study

Somayeh Hosseinpour-Niazi 1*, Parvin Mirmiran 2*, Arefeh Fallah-ghohroudi 1 and Fereidoun Azizi 3

Abstract

Aims: The aim of this study was to investigate whether the background intakes of total dietary fat, monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) modulate the effects of dietary saturated fatty acids (SFA) on metabolic syndrome (MetS).

Material and methods: This population-based cross-sectional study was conducted on a representative sample of 4,677 adults, aged 19 to 84 years. MetS was defined according to the ATP III criteria.

Results: Median intakes of SFA, MUFA and PUFA were 9.5, 9.6 and 5.6% of total energy. High SFA intakes were associated with higher prevalence of MetS, in both individuals with higher and lower median intakes of total fat, MUFA and PUFA.

Conclusions: Our findings indicate that SFA intakes were positively associated with the prevalence of MetS, independent of total dietary fat, MUFA and PUFA intake.

Keywords: Metabolic syndrome, Monounsaturated fatty acid, Polyunsaturated fatty acid, Saturated fatty acid, Interaction

Background

Metabolic syndrome (MetS), a constellation of metabolic abnormalities including glucose intolerance, abdominal obesity, dyslipidemia and hypertension [1], is highly prevalent in Iran. With a prevalence of over 30% in the adult population, this epidemic is foreseen to continue to escalate over the next decade [2]. Health problems associated with this syndrome include diabetes and cardiovascular disease [3]. Although the optimal dietary pattern to reduce progression of MetS has not been well established, a reduction in the proportion of calories from fat, particularly saturated fatty acids (SFA) is generally recommended [4]. Previous studies suggest that reducing the consumption of SFA may be more effective in the prevention of cardiometabolic risk factors [5, 6]. However, the results of recent studies have been conflicting regarding the relative effect of SFA intake on cardiometabolic risk factors; some report no effect [7, 8], while others found a beneficial effect [9, 10]. Background intake of dietary monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) may affect these associations [10, 11]. A recent prospective study investigating the interaction between nutrients and risk of coronary atherosclerosis found that intake of SFA was associated with less progression of coronary atherosclerosis, an association that was significant only among subjects consuming less MUFA [10]. Also in a clinical trial, after categorizing the subjects by the median energy fat percentage, no significant difference was found in high fat diets compared with low fat diets, between the effect of the high SFA and high MUFA diets on insulin sensitivity [12]. An experimental study showed that dietary unsaturated fatty acids interfere with SFA in expression of inflammatory markers [13].

However, previous studies have shown no significant interaction between dietary SFA and PUFA on cardiometabolic risk factors [10, 11]. In a clinical trial study,
fish oil had a beneficial effect on some lipid profiles, regardless of whether the diet contained high or low amounts of SFA [11]. Considering the limited data available on the association between interaction of SFA, MUFA, PUFA and MetS, the aim of this study was to investigate whether background intakes of total dietary fat, MUFA and PUFA modulate the effects of dietary SFA on the MetS and its components, among 19–84 year old subjects, participants of the Tehran Lipid and Glucose Study (TLGS).

Methods
This population based cross-sectional study, conducted within the framework of the TLGS, an ongoing community-based prospective investigation, included a sample of residents under the coverage of 3 medical health centers in District No. 13 of Tehran, the capital city of Iran. The design of the study has been described previously [14]. Briefly, using multistage cluster random sampling methods, 15,005 people, aged ≥3 years, were selected and followed up every 3 years. During the fourth phase of the TLGS (2008–2011), a total of 12,823 subjects completed the examinations and were invited to complete the food frequency questionnaire (FFQ); of the 7,956 who agreed to participate and completed the FFQ, 5,319 were aged 19–84 years. Participants were excluded if they were on any specific diets due to medical history of myocardial infarction (n = 33), stroke (n = 6), cancer (n = 7), reported daily energy intakes outside the range of 800–4200 kcal/d (n = 322) and for missing data on physical activity, or any of anthropometrical measurements, and biochemical variables (n = 92). Also excluded were participants with hyperlipidemia, hyperglycemia and hypertension that had changed their dietary intake (n = 182). Finally, data for 4,677 individuals (2,075 males and 2,602 females) were analyzed (Fig. 1). The design of the study was approved by the ethical committee of the Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, and informed written consent was obtained from all participants.

Dietary assessment
Usual dietary intake was assessed using a 147-item validated semi-quantitative FFQ. The validity and reliability of the FFQ have been described in detail elsewhere [15]. The FFQ consists of a list of foods with a standard serving size, commonly consumed by Iranians. Trained dieticians with at least 5 years of experience in the TLGS...
survey completed the FFQ during face-to-face interviews, asking participants to report their frequency of consumption of a given serving of each food item during the previous year on a daily, weekly, or monthly basis [16]. Details on dietary fat intakes, i.e. type of foods consumed e.g. full fat vs. fat free were obtained. The reported frequency for each food item was converted to a daily intake. Portion sizes of consumed food were then converted to grams using household measures [17]. Energy of each gram of food was obtained from the US Department of Agriculture’s (USDA) Food Composition Table (FCT) by multiplying the gram of consumption of each food by the content of energy per 100 g and total energy intake was calculated by summing up energy intakes from all foods. Composition values for SFA, MUFA and PUFA were obtained from the USDA FCT, because the Iranian FCT with regard to fatty acid intakes is incomplete. Among food items in the FFQ, only ‘kashk’ was not listed in the USDA FCT, and its content of total fatty acid and SFA was determined from the nutritional facts given for this product.

Validity and reliability of the FFQ were assessed in a random sample of 132 subjects, aged 20 y and over. The validity and reliability of the FFQ for total dietary fat was acceptable [18]; correlation coefficient between the FFQ and multiple 24-h recalls was 0.59 and 0.38; and between the two FFQs was 0.43 and 0.42, in males and females, respectively [15]. Also intraclass correlations between the two FFQs and between multiple 24 recalls and the FFQ for SFA, MUFA and PUFA were acceptable in both genders (range 0.51 to 0.74).

Biochemical assessment
After 12 to 14 h of overnight fasting, blood samples were drawn into vacutainer tubes in a sitting position, from all study participants. All blood analyses were done at the TLGS research laboratory on the day of blood collection, using a Selectra 2 autoanalyzer (Vita; Scientific, Spankeren, the Netherlands). Serum triglyceride concentrations were measured using triglyceride kits (Pars Azmoon Inc., Tehran, Iran) by the enzymatic colorimetric test with glycerol phosphate oxidase. HDL cholesterol was measured after precipitation of the apolipoprotein B-containing lipoproteins with phosphotungstic acid. Serum fasting glucose concentration was assayed using an enzymatic colorimetric method with the glucose oxidase technique. Inter- and intra-assay coefficients of variations were both 2.2 % for serum glucose, 2 and 0.5 % for HDL-C and 1.6 and 0.6 % for triglycerides, respectively.

Assessment of other variables
Weight was measured while the subjects were minimally clothed and not wearing shoes, using digital scale and was recorded to the nearest 100 g. Height was measured while subjects were standing without shoes, with their shoulders in a normal position, using a tape fixed to the wall and was recorded to the nearest 0.5 cm. Body mass index (BMI) was calculated as weight (kg) divided by square of height (m²). Waist circumference (WC) was measured at the level of the umbilicus site, using an outstretched tape meter, without pressure to body surfaces and was recorded to the nearest 0.5 cm.

Systolic and diastolic blood pressure was measured using a standard mercury sphygmomanometer, on the right arm after a 15-min rest in a sitting position. Two measurements were taken at 1-min intervals and the average of measurement was recorded as the participant’s blood pressure. Physical activity was assessed using a questionnaire, including a list of common activities of daily life; the frequency and amount of time of activities spent per week over the past 12 month were documented [19]. Levels of physical activity were expressed as metabolic equivalent hours per week (METs h/week) [20] and were categorized as light (>3 METs h/week), moderate (3–6 METs h/week) and heavy (≥6 METs h/week) [20]. Cigarette smoking status was categorized as current smoker, non-smoker and ex-smoker. Additional covariate information including age, medical history, and current use of medications was obtained using an interview questionnaire.

Definition of MetS
MetS was defined as the presence of ≥ 3 of the following 5 components, as recommended by the Adult Treatment Panel III [1]: 1. Low serum HDL cholesterol (<40 mg/dl in men and < 50 mg/dl in women); 2. High serum triglyceride concentrations (≥150 mg/dl); 3. Elevated blood pressure (≥130/85 mmHg); 4. Impaired fasting glucose (fasting plasma glucose concentrations ≥ 110 mg/dl), and 5. Enlarged waist circumference. The cutoff for waist circumference was adopted from the new description of abdominal obesity for Iranian adults, i.e. 95 cm for both genders [21].

Statistical analysis
The Statistical Package for Social Science (version 15.0; SPSS Inc, Chicago IL) was used for all statistical analyses. Significant differences in characteristics and dietary intakes in the categories of total fat intake and SFA using joint categories of higher (≥ median) versus lower (< median) intakes were evaluated using one-way analysis of variance for continuous variables and values were reported as Mean (SD). Chi-square test was used to detect any significant differences in the distribution of participants across quartile categories with regard to qualitative variables. Odds Ratio (ORs) and their 95 % confidence intervals was estimated for the MetS and its components, according to both unsaturated fatty acids (MUFA and PUFA) and SFA using joint categories of higher median
intake versus lower median intakes [22], by multivariate logistic regression models. In all multivariate models, subjects with lower median intakes of both unsaturated fatty acids (MUFA and PUFA) and SFA were considered as the reference.

**Result**
Of 4677 study participants, 44.4 % were male and 55.6 % were female, with a mean age (SD) of 41.7 (13.9) years and had mean BMI of 27.2 (4.7) kg/m². The reported mean (SD) daily intakes were: Total fat 29.9 (6.1) % of total energy intake; SFA 10.2 (2.8) % of total energy intake; MUFA 10.2 (2.8) % of total energy intake and PUFA 6.1 (1.9) % of total energy intake. Baseline characteristics and dietary intakes of the participants according to both total fat and SFA intakes are shown in Table 1. Compared to participants with lower intakes of both SFA and total fat, those with high intake of both SFA

### Table 1: Characteristics and dietary intakes of participants of the Tehran Lipid and Glucose study, according to Total fat and SFA intakes

|                          | SFA < median | SFA ≥ median | P*  |
|--------------------------|--------------|--------------|-----|
|                          | Total fat < median | Total fat ≥ median | Total fat < median | Total fat ≥ median |
| Participants (n)         | 1255         | 1097         | 1010| 1315|
| Age (y)                  | 44.3 ± 14.4a | 42.3 ± 14.1  | 40.3 ± 13.4 | 39.7 ± 13.1 | <0.005|
| Women (%)                | 46.7         | 56.2         | 53.7| 65.2 | <0.005|
| Physical activity (%)    |              |              |     |     | 0.07|
| Light                    | 64.1         | 65.1         | 64.3| 62.3 |
| Moderate                 | 16.9         | 17.0         | 16.3| 17.1 |
| Heavy                    | 19.0         | 17.9         | 19.4| 20.6 |
| Current smoker (%)       | 7.9          | 8.2          | 8.1 | 8.3  | 0.90|
| BMI (kg/m²)              | 27.5 ± 4.6   | 27.3 ± 4.8   | 27.1 ± 4.8 | 27.1 ± 4.8 | 0.06|
| Dietary intake b         |              |              |     |     |     |
| Total energy intake (Kcal/d) | 2329 ± 19.5 | 2447 ± 21.0 | 2287 ± 21.7 | 2425 ± 19.9 | 0.09|
| Protein (% of total energy intake) | 15.2 ± 0.2 | 14.3 ± 0.2 | 16.0 ± 0.2 | 15.1 ± 0.2 | <0.005|
| Carbohydrate (% of total energy intake) | 64.0 ± 0.2 | 59.2 ± 0.2 | 57.6 ± 0.2 | 54.0 ± 0.2 | <0.005|
| Total fat (% of total energy intake) | 26.1 ± 0.3 | 32.8 ± 0.4 | 31.0 ± 0.4 | 38.3 ± 0.3 | <0.005|
| SFA (% of total energy intake) | 7.5 ± 0.3 | 7.9 ± 0.4 | 11.8 ± 0.4 | 12.4 ± 0.4 | <0.005|
| MUFA (% of total energy intake) | 7.7 ± 0.3 | 10.1 ± 0.4 | 9.7 ± 0.4 | 12.7 ± 0.3 | <0.005|
| PUFA (% of total energy intake) | 4.4 ± 0.3 | 7.2 ± 0.4 | 4.5 ± 0.4 | 7.9 ± 0.3 | <0.005|
| Cholesterol (mg/d)       | 186 ± 3.1    | 185 ± 3.2    | 273 ± 3.4 | 258 ± 3.1 | <0.005|
| Fiber (g/d)              | 30.4 ± 15.2  | 29.0 ± 15.0  | 24.1 ± 12.8 | 20.6 ± 12.5 | <0.005|
| Fruit                    | 252 ± 7.6    | 279 ± 8.2    | 285 ± 8.5 | 226 ± 7.8 | <0.005|
| Vegetables               | 278 ± 5.1    | 278 ± 5.7    | 302 ± 5.5 | 264 ± 5.2 | <0.005|
| Meat, poultry and fish   | 60.9 ± 1.2   | 65.6 ± 1.4   | 61.5 ± 1.3 | 63.2 ± 1.3 | <0.005|
| Whole grain              | 179 ± 3.0    | 133 ± 3.3    | 144 ± 3.2 | 111 ± 3.0 | <0.005|
| Refine grain             | 351 ± 4.2    | 291 ± 4.7    | 239 ± 4.5 | 279 ± 4.3 | <0.005|
| Dairy products           | 362 ± 5.8    | 558 ± 6.5    | 293 ± 6.3 | 449 ± 6.0 | <0.005|
| Legumes                  | 46.8 ± 1.2   | 55.8 ± 1.2   | 52.8 ± 1.2 | 42.3 ± 1.2 | <0.005|
| Nuts                     | 5.6 ± 0.3    | 5.8 ± 0.3    | 10.6 ± 0.3 | 9.9 ± 0.3 | <0.005|
| Hydrogenated vegetable oils | 31.5 ± 0.3 | 40.2 ± 0.3 | 35.1 ± 0.4 | 49.5 ± 0.5 | <0.005|
| Non-hydrogenated vegetable oils | 19.2 ± 0.7 | 21.5 ± 0.6 | 18.5 ± 0.5 | 23.8 ± 0.5 | <0.005|

Levels of physical activity were expressed as metabolic equivalent hours per week (METs h/week) and categorized as light (<3 METs h/week), moderate (3–6 METs h/week) and heavy (>6 METs h/week)

Grouped according to < or ≥ median of both Total fat (29.5 % of total energy) and SFA (9.5 % of total energy), with the reference group intake being < median intakes of both MUFA and SFA

BMI body mass index, SFA saturated fatty acid, MUFA monounsaturated fatty acid

*P* value was compared the characteristics across quartiles, using analysis of ANOVA (for age, BMI and dietary intake) and chi-square test (for categorized variables)

Values are Mean (SE), except for variables determined

Dietary intake were adjusted for age, gender and total energy intake using the ANCOVA analysis, except for total energy intake (adjusted for age and gender)
and total fat were slightly younger, while there were no significant differences in the physical activity, smoking status, and BMI. Those subjects with high intakes of both SFA and total fat, consumed less carbohydrate, fiber, fruit, vegetable, whole grain, legume and more total fat and SFA, hydrogenated vegetable oils and non hydrogenated vegetable oils (Table 1).

Table 2 showed the odds ratio of the MetS and its components according to intakes of both SFA and total fat intakes. After adjustment for lifestyle and dietary confounders, high SFA intake (≥9.5 % of total energy) was associated with a 39 % higher prevalence of MetS, among subjects with lower total fat intake (95 % CI: 1.11-1.74) and 22 % higher among subjects with a higher total fat intake (95 % CI: 1.05-1.55), compared with subjects with lower intakes of both. Also the combination of a high SFA and total fat intakes was associated with abnormal glucose homeostasis, elevated blood pressure, and high serum triglyceride concentrations after adjustment for confounding factors.

ORs of the MetS and its components according to intakes of both MUFA and SFA is shown in Table 3. After adjustment for confounding factors, high SFA intake (≥9.5 % of total energy) was associated with higher prevalence of abnormal glucose homeostasis and MetS, whether MUFA intakes was lower or higher than the median intake. Also the combination of a high SFA intakes and a low MUFA intakes was associated with high serum triglyceride concentrations, after adjustment for confounding factors.

Table 4 showed the odds ratio of MetS and its components according to both PUFA and SFA intakes. After

| Enlarged waist circumference | Total fat < median | Total fat ≥ median | Total fat < median | Total fat ≥ median |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Model 1                     | 1.35 (1.11-1.65)   | 1.57 (1.37-1.80)   | 1.40 (1.16-1.67)   |                    |
| Model 2                     | 1.24 (1.00-1.54)   | 1.40 (1.17-1.69)   | 1.30 (1.07-1.57)   |                    |
| Model 3                     | 0.99 (0.71-1.37)   | 1.26 (0.96-1.66)   | 1.37 (1.02-1.83)   |                    |

| Low serum HDL cholesterol   | 1.10 (0.91-1.34)   | 1.07 (0.93-1.22)   | 1.00 (0.83-1.19)   |                    |
| Model 2                     | 1.01 (0.81-1.25)   | 0.90 (0.74-1.10)   | 0.95 (0.78-1.14)   |                    |
| Model 3                     | 0.97 (0.78-1.21)   | 0.86 (0.71-1.04)   | 0.91 (0.75-1.11)   |                    |

| Abnormal glucose homeostasis| 0.94 (0.74-1.19)   | 1.31 (1.13-1.53)   | 1.50 (1.23-1.84)   |                    |
| Model 2                     | 0.97 (0.75-1.25)   | 1.32 (1.07-1.63)   | 1.38 (1.11-1.70)   |                    |
| Model 3                     | 0.87 (0.67-1.14)   | 1.22 (0.98-1.52)   | 1.32 (1.06-1.65)   |                    |

| Elevated blood pressure     | 1.31 (1.04-1.64)   | 1.29 (1.05-1.60)   | 1.49 (1.27-1.74)   |                    |
| Model 2                     | 1.29 (1.01-1.65)   | 1.22 (0.98-1.52)   | 1.44 (1.17-1.77)   |                    |
| Model 3                     | 1.17 (0.91-1.52)   | 1.15 (0.91-1.45)   | 1.32 (1.06-1.64)   |                    |

| High serum triglyceride concentrations | 1.24 (1.00-1.53) | 1.18 (0.97-1.44) | 1.73 (1.50-2.00) |
| Model 2 | 1.06 (0.84-1.34) | 1.10 (0.90-1.35) | 1.42 (1.16-1.73) |
| Model 3 | 0.99 (0.77-1.27) | 1.04 (0.84-1.29) | 1.36 (1.10-1.68) |

| Metabolic syndrome          | 1.16 (0.93-1.45) | 1.66 (1.44-1.93) | 1.40 (1.15-1.71) |
| Model 2 | 1.09 (0.86-1.38) | 1.50 (1.23-1.83) | 1.29 (1.10-1.59) |
| Model 3 | 0.92 (0.70-1.21) | 1.39 (1.11-1.74) | 1.22 (1.05-1.55) |

Model 1 was crude
Model 2 was adjusted for gender, age, smoking status, physical activity, total energy intake, percentage of energy from carbohydrate, percentage of energy from protein, percentage of energy from polyunsaturated fatty acid, total fiber, and cholesterol
Model 3 was further adjusted for BMI
SFA saturated fatty acid
*Grouped according to < or ≥ median of both total fat (29.5 % of total energy) and SFA (9.5 % of total energy), with the reference group intake being < median intakes of both PUFA and SFA
adjustment for lifestyle and dietary confounders, higher SFA intake (≥9.5 % of total energy) was associated with higher prevalence of the MetS and intake of total dietary fat, MUFA and PUFA (higher or lower than the median) did not affect the this association. Also the combination of a high SFA and total fat intakes was associated with abnormal glucose homeostasis, elevated blood pressure, and high serum triglyceride concentrations after adjustment for confounding factors.

**Discussion**

The aim of the current study was to investigate whether the background intake of total dietary fat, MUFA and PUFA modulates the effects of SFA on the MetS and its components. Our findings showed that among Tehranian adults, dietary SFA was associated with high prevalence of the MetS and intake of total dietary fat, MUFA and PUFA (higher or lower than the median) did not affect the this association. Also the combination of a high SFA and total fat intakes was associated with abnormal glucose homeostasis, elevated blood pressure, and high serum triglyceride concentrations after adjustment for confounding factors.

In prospective studies, dietary SFA has been considered a cardiometabolic risk factors [5, 6], but review of the current evidence indicates surprisingly controversial findings; some report no effect [7, 8], while a few found beneficial effects of dietary SFA on chronic disease [9, 10]. Types of dietary fats tend to be intercorrelated and therefore background intakes of dietary MUFA and PUFA may affect the association between dietary SFA and cardiometabolic risk factors [13, 23]. In the only large cohort study with a 14 year follow up, SFA intake was positively associated with chronic heart disease, but

| Table 3 | Odds ratio and 95 % confidence interval for metabolic syndrome and its components according to MUFA and SFA intakes among participants of the Tehran Lipid and Glucose studya |
|---------|--------------------------------------------------------------------------------------------------|
|         | SFA < median | MUFA < median | MUFA ≥ median | SFA ≥ median |
| Enlarged waist circumference                      |                                                        |                |              |              |
| Model 1  | 1            | 1.08 (0.91-1.28) | 1.60 (1.37-1.87) | 1.34 (1.14-1.58) |
| Model 2  | 1            | 1.02 (0.85-1.22) | 1.38 (1.14-1.68) | 1.21 (1.01-1.45) |
| Model 3  | 1            | 0.91 (0.70-1.20) | 1.25 (0.94-1.68) | 1.24 (0.94-1.63) |
| Low serum HDL cholesterol                        |                                                        |                |              |              |
| Model 1  | 1            | 0.97 (0.82-1.14) | 1.05 (0.90-1.23) | 0.97 (0.83-1.14) |
| Model 2  | 1            | 0.94 (0.79-1.12) | 0.90 (0.74-1.10) | 0.88 (0.74-1.06) |
| Model 3  | 1            | 0.93 (0.78-1.11) | 0.87 (0.71-1.05) | 0.86 (0.72-1.03) |
| Abnormal glucose homeostasis                      |                                                        |                |              |              |
| Model 1  | 1            | 0.90 (0.73-1.10) | 1.32 (1.10-1.58) | 1.33 (1.11-1.60) |
| Model 2  | 1            | 0.96 (0.77-1.18) | 1.39 (1.12-1.74) | 1.30 (1.06-1.59) |
| Model 3  | 1            | 0.92 (0.74-1.14) | 1.30 (1.03-1.63) | 1.26 (1.02-1.55) |
| Elevated blood pressure                           |                                                        |                |              |              |
| Model 1  | 1            | 0.98 (0.80-1.19) | 1.43 (1.20-1.71) | 1.23 (1.02-1.48) |
| Model 2  | 1            | 0.95 (0.77-1.17) | 1.30 (1.05-1.63) | 1.13 (0.92-1.39) |
| Model 3  | 1            | 0.91 (0.73-1.13) | 1.20 (0.95-1.51) | 1.08 (0.87-1.33) |
| High serum triglyceride concentrations             |                                                        |                |              |              |
| Model 1  | 1            | 1.12 (0.94-1.35) | 1.76 (1.49-2.07) | 1.38 (1.16-1.64) |
| Model 2  | 1            | 1.01 (0.83-1.22) | 1.36 (1.10-1.68) | 1.19 (0.98-1.44) |
| Model 3  | 1            | 1.00 (0.81-1.22) | 1.30 (1.05-1.63) | 1.16 (0.95-1.42) |
| Metabolic syndrome                                |                                                        |                |              |              |
| Model 1  | 1            | 0.97 (0.80-1.17) | 1.64 (1.38-1.94) | 1.39 (1.17-1.67) |
| Model 2  | 1            | 0.93 (0.76-1.14) | 1.44 (1.17-1.78) | 1.26 (1.14-1.53) |
| Model 3  | 1            | 0.87 (0.69-1.08) | 1.33 (1.05-1.68) | 1.22 (1.05-1.52) |

Model 1 was crude
Model 2 was adjusted for gender, age, smoking status, physical activity, total energy intake, percentage of energy from carbohydrate, percentage of energy from protein, percentage of energy from polyunsaturated fatty acid, total fiber, and cholesterol
Model 3 was further adjusted for BMI
SFA saturated fatty acid, MUFA monounsaturated fatty acid
*aGrouped according to < or ≥ median of both MUFA (9.6 % of total energy) and SFA (9.5 % of total energy), with the reference group intake being < median intakes of both PUFA and SFA*
this association was attenuated and was no longer significant after adjustment for intakes of polyunsaturated fat [23]. A recent prospective study, which investigated the interaction between nutrients and risk of progression of coronary atherosclerosis, found SFA intake to be associated with less progression of coronary atherosclerosis, only significant among subjects consuming less MUFA [10]; the finding was contrary to ours showing that intake of SFA increased the risk of MetS, independent of total dietary fat and MUFA and PUFA [10, 23].

Results on the replacement of MUFA with SFA on cardiometabolic risk factors were inconsistent [12, 24–26]. The effect of substitution of SFA by MUFA on cardiometabolic risk factors may be modulated by total dietary fat [12]. In the KANWN multicenter study, after categorizing the subjects by the median energy fat percentage, in the low fat intake group, high MUFA diet increased insulin sensitivity by 20%, compared to the high SFA diet; however in the high fat diet, no significant difference was found between the effect of the high SFA and high MUFA diet on insulin sensitivity [12]. An observational study also found that changes in insulin resistance were modified by total fat intake, with an improvement in subjects with total fat intake < 35.5% of total energy and no association in subjects with total fat intake > 35.5% of total energy [27], findings consistent with our results. Our findings was showed dietary SFA to be associated with a higher prevalence of abnormal glucose homeostasis, elevated blood pressure, and high serum triglyceride concentrations, only among subject with high intake of total dietary fat.

Our findings show high prevalence of MetS and abnormal glucose homeostasis among subjects with high

### Table 4 Odds ratio and 95% confidence interval for metabolic syndrome and its components according to PUFA and SFA intakes among participants of the Tehran Lipid and Glucose study

|                     | SFA < median | SFA ≥ median | SFA < median | SFA ≥ median |
|---------------------|--------------|--------------|--------------|--------------|
|                     | PUFA < median | PUFA ≥ median | PUFA < median | PUFA ≥ median |
| **Enlarged waist circumference** |              |              |              |              |
| Model 1             | 1            | 1.08 (0.91-1.28) | 1.06 (0.71-1.27) | 1.24 (0.94-1.63) |
| Model 2             | 1            | 1.02 (0.85-1.22) | 1.04 (0.70-1.25) | 1.21 (0.88-1.45) |
| Model 3             | 1            | 0.91 (0.70-1.20) | 0.99 (0.69-1.22) | 1.04 (0.70-1.58) |
| **Low serum HDL cholesterol** |            |              |              |              |
| Model 1             | 1            | 0.97 (0.83-1.14) | 1.05 (0.90-1.23) | 0.97 (0.82-1.14) |
| Model 2             | 1            | 0.88 (0.74-1.06) | 0.90 (0.74-1.10) | 0.94 (0.79-1.12) |
| Model 3             | 1            | 0.86 (0.72-1.03) | 0.87 (0.71-1.05) | 0.93 (0.78-1.11) |
| **Abnormal glucose homeostasis** | |              |              |              |
| Model 1             | 1            | 0.90 (0.73-1.10) | 1.32 (1.15-1.58) | 1.37 (1.11-1.60) |
| Model 2             | 1            | 0.96 (0.77-1.18) | 1.26 (1.09-1.44) | 1.30 (1.06-1.59) |
| Model 3             | 1            | 0.92 (0.74-1.14) | 1.15 (1.06-1.33) | 1.26 (1.02-1.55) |
| **Elevated blood pressure** | |              |              |              |
| Model 1             | 1            | 1.23 (0.98-1.48) | 1.43 (1.20-1.71) | 0.98 (0.80-1.19) |
| Model 2             | 1            | 1.13 (0.92-1.39) | 1.30 (0.95-1.63) | 0.95 (0.77-1.17) |
| Model 3             | 1            | 1.08 (0.87-1.33) | 1.20 (0.85-1.51) | 0.91 (0.73-1.13) |
| **High serum triglyceride concentrations** | |              |              |              |
| Model 1             | 1            | 1.38 (1.16-1.64) | 1.26 (0.79-2.07) | 1.12 (0.94-1.35) |
| Model 2             | 1            | 1.19 (0.98-1.44) | 1.16 (0.70-1.68) | 1.01 (0.83-1.22) |
| Model 3             | 1            | 1.16 (0.95-1.42) | 1.10 (0.55-1.63) | 1.00 (0.81-1.22) |
| **Metabolic syndrome** | |              |              |              |
| Model 1             | 1            | 0.97 (0.80-1.17) | 1.64 (1.38-1.94) | 1.39 (1.17-1.67) |
| Model 2             | 1            | 0.93 (0.76-1.14) | 1.44 (1.17-1.78) | 1.26 (1.10-1.53) |
| Model 3             | 1            | 0.87 (0.69-1.08) | 1.33 (1.05-1.68) | 1.22 (1.05-1.52) |

Model 1 was crude
Model 2 was adjusted for gender, age, smoking status, physical activity, total energy intake, percentage of energy from carbohydrate, percentage of energy from protein, percentage of energy from polyunsaturated fatty acid, total fiber, and cholesterol
Model 3 was further adjusted for BMI

SFA saturated fatty acid, PUFA polyunsaturated fatty acid

*Grouped according to < or ≥ median of both PUFA (5.6% of total energy) and SFA (9.5% of total energy), with the reference group intake being < median intakes of both PUFA and SFA*
intake of SFA, independent of dietary PUFA. Consistent with our results, epidemiologic and experimental studies have shown no significant interaction between SFA and PUFA [10, 11]. In a clinical trial study, fish oil had a beneficial effect on some lipid profiles, regardless of whether the diet containing high or low amounts of SFA [11].

Our study has several strengths. In the current study, we evaluate whether total dietary fat, PUFA and MUFA intakes influence relations between SFA and Mets and its components. We found that the association between the SFA intake and some components of MetS is modulated by total dietary fat, as suggested by some previous studies [12, 27]. Also, our findings suggest that dietary SFA was associated with MetS, independent of PUFA and MUFA intake, which may have important implications for MetS prevention in populations.

Some limitations should be considered, one being the use of UASD FCT to determine the intakes of PUFA, MUFA and SFA, because of not having a complete Iranian FCT. Given the cross-sectional design, we could not determine causality between interaction of different type of fatty acids and the MetS and its components. Future studies using longitudinal data are needed to determine these effects. In addition, this study included only healthy adults, and our findings cannot be extrapolated to other populations.

Conclusion
Our findings indicate that SFA intakes were positively associated with the prevalence of MetS, independent of total dietary fat, MUFA and PUFA intake. However total dietary fat may modulate the association between SFA and some components of MetS, results emphasizing that both the quality and quantity of dietary fat are relevant with Mets and cardiometabolic risk factors.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
(SH-N, PM, AF-G) conception and design, analysis and interpretation of data; (SH-N) drafting the article; (FA) critical revision. (SH-N, PM, AF-G) final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgment
The authors wish to acknowledge to Ms N. Shiva for critical editing of English grammar and syntax of the manuscript. This study was funded by the Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (grant 750).

Author details
1Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 15 June 2015 Accepted: 26 June 2015
Published online: 11 July 2015

References
1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Franklin BA, Gordon DJ, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.
2. Azizi F, Salehi P, Etemad A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population. Tehran Lipid and Glucose Study. Diabetes Res Clin Pract. 2003;61:29–37.
3. Zarch SW. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations. Minerva Endocrinol. 2006;54:195–214.
4. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. American heart association’s dietary guidelines: revision 2000: a statement for healthcare professionals from the nutrition committee of the american heart association. Circulation. 2000;102:2284–99.
5. Chiue SE, Rimm EB, Sandhu RK, Bernstein AM, Rexrode KM, Manson JE, et al. Dietary fat quality and risk of sudden cardiac death in women. Am J Clin Nutr. 2012;96:498–507.
6. Trichopoulou A, Psaltopoulou T, Orfanos P, Trichopoulou D. Diet and physical activity in relation to overall mortality amongst adult diabetics in a general population cohort. J Intern Med. 2006;259:583–91.
7. Harding AH, Day NE, Khaw KT, Bingham S, Luben R, Welch A, et al. Dietary fat and the risk of clinical type 2 diabetes: the European prospective investigation of Cancer-Norfolk study. Am J Epidemiol. 2004;159:73–82.
8. Meyer KA, Kushiy L, Jacobs JR DR, Folsom AR. Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care. 2001;24:1528–33.
9. Soino M, Laakso M, Lehto S, Hakala P, Rönnemaa T. Dietary fat predicts coronary heart disease events in subjects with type 2 diabetes. Diabetes Care. 2003;26:619–24.
10. Mozaffarian D, Rimm EB, Herrington DM. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. Am J Clin Nutr. 2004;80:1175–84.
11. Nordøy A, Hatcher LF, Ullmann DL, Connor WE. Individual effects of dietary saturated fatty acids and fish oil on plasma lipids and lipoproteins in normal men. Am J Clin Nutr. 1993;57:634–9.
12. Vessby B, Unisutapa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, et al. Substituting dietary saturated fatty acids for monounsaturated fatty acids impairs insulin sensitivity in healthy men and women: the KAMHU study. Diabetologia. 2001;44:312–9.
13. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, reduce the expression of cyclooxygenase-2 mediated through Toll-like receptors 4. J Biol Chem. 2001;276:16683–9.
14. Azizi F, Gharibiaran A, Momennan AA, Hadaefgh F, Mirimian P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5.
15. Mirimian P, Hosseini-Esfahani F, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran Lipid and Glucose Study. Public Health Nutr. 2009;13:645–62.
16. Willett W. Food frequency methods. In: Nutritional Epidemiology. 2nd ed. New York, PA: Oxford University Press; 1998. p. 74–94.
17. Ghafarpour M, Houshiar Rad A, Khanfar H. The manual for household measures, cooking yields factors and edible portion of food. Tehran: Keshavarz Press; 1999.
18. Willett W. Reproducibility and validity of food-frequency questionnaire. In: Nutritional Epidemiology. 2nd ed. New York, PA: Oxford University Press; 1998. p. 101–47.
19. Krishka AM, Knowler WC, Lapte RE, Drash AL, Wing RR, Blair SN, et al. Development of questionnaire to examine relationship of physical activity in relation to overall mortality amongst adult diabetics in a general population cohort. J Intern Med. 2006;259:583–91.
20. Ainsworth BE, Haskell WL, Leon AS, Jacobs DRJR, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25:71–80.
21. Azizi F, Hadaefgh F, Khahi D, Esteghamati A, Hosseini Panah F, Delavari A, et al. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch Iran Med. 2010;13:426–8.
22. Mozaffarian D, Ascherio A, Hu FB, Stampfer MJ, Willett WC, Siscovick DS, et al. Interplay between different polysaturated fatty acids and risk of coronary heart disease in men. Circulation. 2005;111:157–64.
23. Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997;337:1491–9.

24. Hodson L, Skeaff CM, Chisholm WA. The effect of replacing dietary saturated fat with polyunsaturated or monounsaturated fat on plasma lipids in free-living young adults. Eur J Clin Nutr. 2001;55:908–15.

25. Tierney AC, McMonagle J, Shaw DJ, Gulseth HL, Helal O, Saris WH, et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome—LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond). 2011;35:800–9.

26. Bos MB, de Vries JH, Feskens EJ, van Dijk SJ, Hoelen DW, Siebelink E, et al. Effect of a high monounsaturated fatty acids diet and a Mediterranean diet on serum lipids and insulin sensitivity in adults with mild abdominal obesity. Nutr Metab Cardiovasc Dis. 2010;20:591–8.

27. Corpeleijn E, Feskens EJ, Jansen EH, Mensink M, Saris WH, de Bruin TW, et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia. 2006;49:2392–41.